NCT04835038

Brief Summary

  1. 1.Title: Effects of Sodium Bicarbonate Ringer's Injection and Sodium Lactated Ringer's Injection on postoperative acute kidney injury in patients undergoing major abdominal surgery: a randomized, controlled, open-label clinical study
  2. 2.Objective: To evaluate the effect of BRS and LRS infusion on acute renal injury in patients undergoing major abdominal surgery
  3. 3.Primary outcome: Incidence of AKI at 28 days postoperative (defined as acute kidney injury, according to Kidgo 2012 definition and classification).
  4. 4.Study Design: Randomized, controlled, open-label clinical study.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
3,400

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Jun 2021

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 6, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 8, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

June 1, 2021

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2023

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2023

Completed
Last Updated

April 12, 2023

Status Verified

April 1, 2023

Enrollment Period

2 years

First QC Date

April 6, 2021

Last Update Submit

April 11, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Postoperative acute renal injury

    The incidence of AKI at 28 days after surgery (Acute kidney injury is defined and graded according to KIDGO 2012)

    28 days after surgery

Study Arms (2)

Sodium Bicarbonate Ringer's Injection group

EXPERIMENTAL

Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)

Drug: Sodium Bicarbonate Ringer's Injection

Sodium Lactated Ringer's Injection group

ACTIVE COMPARATOR

Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)

Drug: Sodium Lactated Ringer's Injection

Interventions

Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)

Sodium Bicarbonate Ringer's Injection group

Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)

Sodium Lactated Ringer's Injection group

Eligibility Criteria

Age20 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ASA grade Ⅰ-Ⅲ.
  • patients aged between 20 and 70, signed informed consent form, and are willing to participate in the study.
  • BMI ≤ 30kg/m2.
  • elective major abdominal surgery for the first time (radical resection of ovarian cancer, radical resection of cervical cancer, radical resection of gastric cancer, radical resection of colorectal cancer, radical resection of bladder tumor and radical resection of prostate tumor).
  • NYHA cardiac function grade Ⅰ-Ⅲ.
  • the function of liver and kidney is normal before operation.
  • the blood coagulation function was normal before operation.
  • hemoglobin \> 70g/L.
  • sinus rhythm was detected by electrocardiogram and there were no other malignant arrhythmias.

You may not qualify if:

  • Emergency surgery.
  • liver and kidney surgery.
  • complicated with chronic respiratory diseases and FEV1/FVC \< 70%.
  • the operation time is less than 2 hours.
  • patients with mental illness or cognitive impairment.
  • uncontrolled hypertension with blood pressure higher than 180 × 100mmHg.
  • patients with hypothyroidism.
  • pregnant or lactating patients. -

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tongji hospital

Wuhan, Hubei, 27-430030, China

RECRUITING

MeSH Terms

Conditions

Acute Kidney Injury

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Officials

  • Shiyong Li

    Tongji Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator, Associate professor

Study Record Dates

First Submitted

April 6, 2021

First Posted

April 8, 2021

Study Start

June 1, 2021

Primary Completion

June 1, 2023

Study Completion

August 1, 2023

Last Updated

April 12, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will not share

Locations